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Small GTPaseSince their discovery in 1986, Ral (Ras-like) GTPases have emerged as critical regulators of diverse cellular func-
tions. Ral-selective guanine nucleotide exchange factors (RalGEFs) function as downstream effectors of the Ras
oncoprotein, and the RalGEF–Ral signaling network comprises the third best characterized effector of
Ras-dependent human oncogenesis. Because of this, Ral GTPases as well as their effectors are being explored
as possible therapeutic targets in the treatment of RASmutant cancer. The two Ral isoforms, RalA and RalB, inter-
act with a variety of downstream effectors and have been found to play key and distinct roles in both normal and
neoplastic cell physiology including regulation of vesicular trafﬁcking, migration and invasion, tumor formation,
metastasis, and gene expression. In this reviewwe provide an overview of Ral biochemistry and biology, and we
highlight recent discoveries.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Identiﬁed initially as Ras-like (Ral) proteins, the Ral small GTPases
are members of the Ras branch of the Ras superfamily of small GTPases
[1]. RALAwas identiﬁed initially using oligonucleotide probes to identify
RAS-related genes in a cDNA library established from immortalized
simian B-lymphocytes [2]. Three years later, using the simian RALA
cDNA as a probe, human RALA and a related RALB gene were identiﬁed
from a human pheochromocytoma cDNA library [3]. Subsequently,
single RAL orthologs were identiﬁed in Caenorhabditis elegans (RAL-1)
[4] and Drosophila (RalA) [5] (Fig. 1). Interestingly, although there are
well-conserved RAS orthologs in yeast, no RAL orthologs are present in
Saccharomyces cerevisiae or Schizosaccharomyces pombe.
The three human RAS genes (HRAS, KRAS and NRAS) comprise one of
the most frequently mutated gene families in human cancers [6].minal amino acid; DMBA, 7,12-
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1 919 966 9673.Consequently, they have been the subject of intense research scrutiny
and cancer drug discovery. Initially, the discovery of Ral proteins simply
added to a rapidly growing roster of proteins that now comprise a large
superfamily of N150 Ras-related small GTPases [1]. However, with
discoveries that Ral GTPases are key regulators of vesicular trafﬁcking
and are effectors of Ras oncoprotein-driven growth transformation,
Ral proteins stepped into the spotlight in 2003 to bask in their “15 mi-
nutes of fame” [7]. Since those initial ﬁndings, more discoveries on the
role of Ral in normal and cancer cell physiology have ensured that
their “fame”will last considerablymore than 15 minutes. In this review,
we summarize our current knowledge on Ral GTPases andwe highlight
recent ﬁndings in Ral function.2. Ral proteins
2.1. Ral protein structure
The highly related human RalA and RalB isoforms share 82% overall
amino acid sequence identity (Fig. 1A) and are members of the Ras
branch of the Ras superfamily (Fig. 1B). They share 46–51% sequence
identity and domain architecture with Ras proteins [8]. However, Ral
proteins contain an N-terminal 11 amino acid extension not found in
Ras, accounting for the 11 residue shift in numbering compared with
Ras residue numbering (Fig. 1C). This is followed by the G domain, in-
volved in GTP binding and hydrolysis, and the C-terminal membrane
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Fig. 1. Evolutionary conservation of Ral small GTPases. A. Human and invertebrate Ral orthologs exhibit strong sequence identity. The RalA and RalB isoforms are found in all vertebrate
species [17]. There is one Ral ortholog in C. elegans (Ce) and D. melanogaster (Dm). Overall sequence identity was determined by CLUSTALWmultiple sequence alignment. B. Ral GTPases
are members of the Ras branch of the Ras superfamily. Shown here is a comparison with the four Ras proteins and representative members of the Ras family. The dendrogram was
generated by CLUSTALW multiple sequence alignment. C. Dendrogram showing sequence relationship of human and invertebrate Ral proteins. D. Ral domain structure. Human RalA
and RalB G domains (12–176) shares 88% sequence identity and contain the SI and SII domains that change in conformation during GDP–GTP cycling and are involved in interaction
with regulators and effectors. The switch regions are conserved between human Ral proteins and Drosophila Ral and differ by a single residue in each switch in C. elegans Ral (identical
residues indicated in blue text). The hypervariable (HV) C-terminus (50% identity) consists of the membrane targeting region and contains key post-translational phosphorylation sites
that regulate Ral subcellular localization and effector interaction. Multiple sequence alignment was done by ClustalW analyses and domain topology by SMART analyses. Numbers
correspond to the human Ral amino acid sequences.
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the C-terminal hypervariable regions (50% shared identity) (Fig. 1C).
Like Ras, Ral proteins cycle between inactive GDP-bound and active
GTP-bound states (Fig. 2A). RalA and RalB share complete sequence
identity in the switch I (SI) and II (SII) sequences that change conforma-
tion duringGDP–GTP cycling [8] (Fig. 1D). As described below, SI and SII
are involved in recognition by both regulators and effectors. The conser-
vation of SI and SII sequences in Drosophila and C. elegans Ral proteins
support their interaction with conserved regulators and effectors.
Similar to Ras, the intrinsic GDP–GTP exchange and GTP hydrolysis
activities of Ral GTPases are very weak, with each activity accelerated
by Ral-selective guanine nucleotide exchange factors (RalGEFs) and
GTPase activating proteins (RalGAPs), respectively (Fig. 2A). RalGEFs
stimulate guanine nucleotide exchange. With intracellular levels ofGTP approximately 10-fold higher than GDP, RalGEF stimulation favors
formation of Ral-GTP. Ral GTPase activating proteins (RalGAPs) catalyze
the hydrolysis of the bound GTP, returning Ral to an inactive conforma-
tion. When bound to GTP, RalA and RalB can interact with the same
array of downstream effector proteins and mediate numerous cellular
processes.
2.2. RalGEFs
The ﬁrst RalGEF identiﬁed, Ral guanine nucleotide dissociation stim-
ulator (RalGDS) (Fig. 2B), was found by yeast two-hybrid screens per-
formed in the early 1990s to identify Ras effectors [9–11]. RalGDS was
found to catalyze nucleotide exchange on both RalA and RalB but not
on other small GTPases including members of the Ras, Rho, and Rab
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Fig. 2. Regulators of the Ral GDP-GTP cycle. A. Regulation of Ral GDP-GTP cycling. Ral-selective GEFs and GAPs accelerate the low intrinsic exchange and GTP hydrolysis activities to pro-
mote formation of active GTP-bound and inactive GDP-bound Ral. B. The RalGEFs are highly conserved across species. All RalGEFs contain a CDC25 homology domain, which is responsible
for catalytic activity. There are four human isoforms of RalGEF that contain Ras-association (RA) domain. These isoforms also contain a Ras exchangermotif (REM) that likely stabilizes the
CDC25 homology domain and is essential for RalGEF catalytic activity. There is one homolog in C. elegans and two inDrosophila. The RalGEF homolog in C. elegans ismost similar to RalGDS.
The RalGPS RalGEFs lack a REM domain and do not associate with Ras, but instead contain a pleckstrin homology (PH) domain. RGL4 contains a CDC25 homology domain, but lacks a REM,
RA or PH domain. C. The RalGAPs are heterodimeric complexes formed by either a RalGAPα1 or RalGAPα2 catalytic subunit with the regulatory RalGAPβ subunit. The RalGAPβ subunit
serves to regulate the catalytic activity of the RalGAPα subunits, similar to TSC1 regulation of TSC2. Percentages indicate sequence identity with the RalGAPα1 catalytic domain. Orthologs
of the human RalGAPα and RalGAPβ subunits are present in C. elegans and Drosophila. Multiple sequence alignment and sequence identity were determined by ClustalW analyses and
domain topology by SMART analyses.
2978 L.R. Gentry et al. / Biochimica et Biophysica Acta 1843 (2014) 2976–2988families. Subsequent yeast two-hybrid library screening studies using
H-Ras, R-Ras, TC21/R-Ras2, and Rit as baits identiﬁed three additional
RalGEF proteins that were named Rgl (RalGDS-like), Rgl2/Rlf, and Rgl3
[12–15]. These RalGEFs contain a common domain architecture includ-
ing an N-terminal Ras exchanger motif (REM) domain followed by a
CDC25 homology domain (RasGEF) and a C-terminal Ras-association
(RA) domain (Fig. 2B) [16]. The CDC25 homology domain shares
sequence identity with the catalytic domains of RasGEFs [17]. In addi-
tion to the three Ras isoforms, other Ras family small GTPases can also
bind and activate the RA domain-containing RalGEFs [18].
RalGPS1 and RalGPS2 (Ral GEF with PH domain and SH3-binding
motif) comprise a second distinct family of RalGEFs [19–21]
(Fig. 2A). These two related proteins (63% identity) contain an
N-terminal CDC25 homology RasGEF but lack a REM and RAdomain. In-
stead, they contain a C-terminal pleckstrin homology (PH) domain.Additionally, they possess is a central proline-rich sequence with
PxxP motifs recognized by Src homology 3 (SH3) domain-containing
proteins.
The absence of an RA domain uncouples these RalGEFs from direct
association with Ras family small GTPases. Instead, the PH domain has
been shown to be sufﬁcient for membrane targeting and necessary for
Ral activation [19]. The regulation of these RalGEFs is poorly understood,
but some evidence suggests that RalGPS2 plays a role in regulating the
actin cytoskeleton [21]. Interestingly, members of both RalGEF
subclasses have been implicated in cytokinesis [22].
Another RalGEF, now designated RGL4, was identiﬁed originally as a
RalGDS-related (Rgr) oncogene in a DMBA (7,12-dimethylbenz[α]an-
thracene)-induced rabbit squamous cell carcinoma [23]. However,
while RGL4 does contain a CDC25 homology domain, it lacks a well-
deﬁned RA or PH domain (Fig. 2B). Furthermore, while the other
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also been described to activate other Ras family small GTPases [24].
2.3. RalGAPs
Although the existence of RalGAPs was ﬁrst reported in 1991 [25],
only recently has themolecular identiﬁcation of RalGAPs been achieved
(Fig. 2C). Work done by Feig and colleagues in the early 1990s detected
and characterized RalGAP activity in brain and testes cytosolic extracts,
and the putative RalGAP activity was distinct in size from Ras or Rho
GAPs [25]. Subsequently, using a GTPase-deﬁcient, persistently GTP-
boundmutant of RalA for afﬁnity chromatography, two distinct RalGAP
complexes were identiﬁed in brain cytosol [26]. Each heterodimeric
complex consists of a shared regulatory RalGAPβ subunit and one of
two related catalytic RalGAPα1 and α2 subunits (53% overall sequence
identity) (Fig. 2A,C). Independently, Saltiel and colleagues used a similar
RalA afﬁnity puriﬁcation approach and identiﬁed RalGAPα2 (RGC2) and
RalGAPβ (RGC1) as components of a Ral-selective GAP [27].
RalGAPα1 (GARNL1/TULIP1) and RalGAPα2 (AS250; Akt substrate
of 250 kDa) were identiﬁed previously as proteins with sequence
identity with the GAP catalytic domain of TSC2 (also known as tuberin)
[28,29] (Fig. 2B) and distinct from the RasGAP catalytic domain [17].
RalGAPα2 was also identiﬁed to form a complex with RalGAPβ
(KIAA1219). TSC2 is the catalytic subunit of a GAP selective for the
Rheb small GTPases, another member of the Ras branch of the Ras
superfamily [1]. However, TSC2 alone is not sufﬁcient for RhebGAP
activity and requires heterodimer formation with TSC1 (also known
as hamartin). Hence, the active RalGAPα/β complexes share both
sequence and structural similarities with the heterodimeric tuberous-
sclerosis (TSC) complex [30]. Although RalGAPβ lacks sequencesimilarity with Tsc1, it serves an analogous role in stabilizing RalGAPα
and is required for RalGAP activity. RalGAPβ is expressed ubiquitously,
whereas more variable expression proﬁles are seen for the two
RalGAPα subunits. RalGAPs are conserved in evolution, with orthologs
of both subunits found in C. elegans and Drosophila (Fig. 2B) [26,31].
The RalGAPα GAP catalytic domains of C. elegans (HGAP-1) and
Drosophila (CG5521) share 37–39% and 58–59% sequence identity, re-
spectively, with the GAP catalytic domains of their human counterparts.
RalGAP accelerates the GTPase activity of both RalA and RalB but not
for other small GTPases tested (H-Ras, Rap1, Rheb, RhoA, Ran and
Rab27) [26,27,31]. The RalGAPα subunits share 53% overall sequence
identity and 83% sequence identity in their GAP domains (Fig. 2C,D).
Additionally, RalGAPα2 is subject to insulin-stimulated phosphoryla-
tion by the AKT serine/threonine kinase, analogous to a similar mecha-
nismof AKT regulation of TSC2 [32]. As with TSC2, AKT phosphorylation
of RalGAPα2 impaired the ability of the RalGAP complex to catalyze
RalA-GTP hydrolysis. This is not due to altered intrinsic GAP activity
but to a reduced RalA interaction with RalGAPα2.
3. Ral effectors
Like Ras and other small GTPases, Ral interacts with a number of
effector proteins when bound to GTP (Fig. 3). However, unlike Ras, the
Ral-binding domains (RBD) lack primary sequence identity. The
best characterized Ral effectors are RalBP1/RLIP76 and the Sec5 and
Exo84 subunits of the octameric exocyst complex. The evolutionarily
conserved exocyst complex mediates the tethering of post-Golgi secre-
tory vesicles to the plasma membrane prior to exocytic fusion [33]. The
exocyst subunits may also exist as monomers or subcomplexes, and can
possess non-exocyst functions. Ral interaction with each subunit occurs
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Fig. 3. Ral effectors and effector functions. Active Ral can bind to a variety of downstream effectors andmodulate numerous cellular activities. RalBP1 acts as a RhoGAP aswell as a scaffold
for other proteins that regulate endocytosis and other cellular processes. Ral association with Sec5 or Exo84 can regulate exocyst-dependent and -independent processes. Other effector
processes include regulation of cell cycle progression through PLD1-dependent cytokinesis and cytoskeletal changes throughﬁlaminA, IP3 signaling through PLCδ1, and gene transcription
through ZONAB. Ral activation also stimulates signaling pathways that lead to the activation of various transcription factors (TF), stimulating gene expression.
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membrane and with Exo84with intracellular vesicles [34,35]. Although
RalA and RalB can interact with the same set of effectors in vitro, as
described below, the distinct biological functions of RalA and RalB are
mediated by differences in subcellular localization, leading to their
interaction with distinct subsets of effectors.
The structures of Ral in complex with the RBDs of these three effec-
tors have been determined. Whereas the Sec5 RBD interacts with SI
alone [36], Exo84 [37] and RalBP1 [38] RBD interaction involves both
SI and SII [39]. Consistent with 100% conservation of SI and SII residues,
and residues involved with effector binding, where studied, RalA and
RalB interact with the same set of effectors in vitro.
3.1. RalBP1/RLIP76
The ﬁrst Ral effector described, RalBP1 (Ral-binding protein 1; also
called RLIP76 or RIP1), was identiﬁed in screens for proteins that
bound preferentially to activated RalA [40–42]. RalBP1 orthologs are
found in Drosophila and C. elegans. RalBP1 contains a RhoGAP catalytic
domain that has activity for the Cdc42 and Rac small GTPases, members
of the Rho branch of the Ras superfamily [1]. Cdc42 stimulates ﬁlopodia
formation whereas Rac stimulates lamellipodia formation. Thus, RalBP1
provides a link between Ral and modulation of the actin cytoskeleton
changes that drive these cellular activities [40].
In addition to its RhoGAP domain, RalBP1 has additional functions
(Fig. 3). Two ATP binding motifs have been identiﬁed in RalBP1 and
shown to be important for transport function involving glutathione
conjugates of electrophilic compounds [43,44]. This transport function
may facilitate the cellular export of chemotherapeutic drugs and
radiation-induced oxidative damage byproducts [45]. RalBP1 overex-
pression has been found in a spectrum of human cancers, and suppres-
sion of RalBP1 expression can impair tumorigenic growth in vivo [46].
However, phenotypes attributed to RalBP1 do not necessarily implicate
their role in Ral signaling [47].
RalBP1 also functions as a scaffold and interacts with a spectrum of
functionally distinct proteins that regulate endocytosis and signaltransduction (Fig. 3). The AP2 adaptor complex, a regulator of
clathrin-mediated endocytosis from the plasma membrane, associates
with the N-terminal region of RalBP1 [48]. The Eps homology (EH)
domain-containing proteins Reps1 and Reps2 (POB1) were identiﬁed
as proteins that interacted with the C-terminus of RalBP1 [49,50].
These proteins are known to be important for receptor tyrosine
kinase-regulated endocytosis, with Reps1 interacting with Rab11-FIP2
and Reps2 binding Epsin and Eps15 [51,52].
Another protein that associates with the RalBP1 C-terminus is cyclin
B1 [53]. In turn, the RalBP1-bound cyclin B1 complexes with Cdk1, with
Cdk1 phosphorylation of Epsin preventing endocytosis during mitosis.
This activity was shown to be mediated by RalA activation.
RalBP1 has been implicated as a key effector for several Ral-driven
processes. In these studies, the typical approach has been the utilization
of mutants of Ral that are selectively impaired in effector interaction.
The D49N substitution impairs RalBP1 but not Sec5 or Exo84 effector
binding, whereas the D49E mutation has the opposite consequence
[40,54,55]. For example, shRNA silencing analyses determined that
RalB but not RalA was required for invadopodia formation in pancreatic
cancer cell lines [56]. RalB D49E but not D49N could rescue loss of
endogenous RalB and restore invadopodia formation, indicating that
RalBP1 was a critical effector for this RalB activity. This RalBP1 function
was GAP-independent but abolished by mutation of the ATP binding
motifs [56].
RalAwas shown to utilize RalBP1 to regulatemitochondrialﬁssion at
mitosis [57]. Mitochondria exist as dynamic interconnected networks
that aremaintained through a balance of fusion andﬁssion. Fission facil-
itates equal distribution of mitochondria to daughter cells during mito-
sis. Fission is controlled by the GTPase DRP1 on the outer mitochondrial
membrane. RalA was found to recruit RalBP1 to the mitochondria,
where RalBP1 acts as a scaffold to facilitate cyclin B/Cdk1 phosphoryla-
tion of Drp1 to promote mitochondrial ﬁssion. Suppression of either
RalA or RalBP1 expression caused a loss of mitochondrial ﬁssion at
mitosis.
Recently, RalBP1 was shown to be necessary and sufﬁcient for
RalA-driven mislocalization of the cyclin-dependent kinase inhibitor
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epithelial cells [58]. This function appeared to require an intact RhoGAP
domain.3.2. The Sec5 and Exo84 subunits of the exocyst
The best characterized Ral effectors are two components of the
exocyst complex, Sec5 and Exo84 [54,55,59]. The association of Ral
with both Sec5 and Exo84 has been found to be important in exocytosis.
Ral regulates the subcellular localization of the exocyst throughmediat-
ing Sec5-paxillin association and the assembly of the octameric exocyst
complex by interacting with Sec5 and Exo84 [55,60]. Ral interaction
with Sec5 may also regulate exocyst-independent functions.
Recent evidence suggests that Ral engages exocyst subunits to
perform a variety of cellular processes independent of their roles in exo-
cytosis. White and colleagues found that the association of RalB with
Sec5 is critical in the innate immune response [61]. RalB binding to
Sec5 leads to an interaction of Sec5 with TBK1, a protein kinase
known to regulate NF-κB signaling. Intriguingly, TBK1 has recently
been identiﬁed in siRNA screens as a synthetic lethal partner of activat-
ed K-Ras [62], although a subsequent study failed to support this rela-
tionship [63].
Recently, a mechanism where the integrin αvβ3 recruited a
K-Ras–RalB complex to the plasma membrane to activate TBK1 and
NF-κB signaling was identiﬁed (Fig. 3) [64]. This signaling mecha-
nism regulated tumor initiation and growth.
The association of RalB with the exocyst has also been shown to
regulate macroautophagy [34]. When cells are grown in nutrient-rich
conditions, RalB engages Sec5. Upon nutrient starvation, RalB then
engages Exo84 and the exocyst, leading to an upregulation of
autophagosome formation. This process ismediated through the assem-
bly of the ULK1 serine/threonine kinase and Beclin1–VPS34 complexes
on the exocyst. Autophagy has emerged as a key component of
Ras-driven transformation in a variety of cell types, perhaps highlight-
ing an underlying importance of Ras–RalGEF signaling in tumor cell
autophagy.3.3. Other effectors
One lesser-characterized Ral effector is phospholipase D1 (PLD1)
[65,66]. However, unlike other effectors, the association with Ral is not
GTP-dependent and instead the association is with the N-terminal 11
amino acid extension (Fig. 1D). PLD1 is best known for its role in
converting phosphotidylcholine to phosphatidic acid and choline in
response to G-protein coupled receptor (GPCR) stimulation. Recent
evidence shows that RalA is necessary for the PLD1-mediated stimula-
tion of mTORC1 signaling [67]. Furthermore, the RalA–PLD1 interaction
has been shown to promote proper p27 localization, thus allowing for
proper TGF-β signaling [58]. The interaction of both RalA and RalB
with PLD1 has been shown to be critical for HeLa cell cytokinesis [22].
Filamin is an important component of the actin cytoskeleton and is
involved in actin crosslinking and lamellipodia formation. The associa-
tion of RalAwith ﬁlaminwas found to be important for ﬁlopodia forma-
tion in Swiss-3T3 cells [68]. Additionally, RalA did not induce ﬁlopodia
in a human melanoma cell line that lacks expression of ﬁlamin.
Lastly, active RalA has been shown to engage the transcription
factor ZONAB (zonula occludens 1-associated nucleic acid binding
protein) in a cell density dependent manner in MDCK cells [69]. At
high cell densities, RalA engages ZONAB, unlocking the transcription
of ZONAB targets, but it is unclear which genes are turned on [69].
While a direct role for Ral associationwith these lesser-studied effec-
tors has not been found in Ral-driven cancers, their important roles
in mitosis, motility, and gene regulation make them intriguing tar-
gets as Ral studies progress.4. Post-translational modiﬁcation and regulation of Ral function
RalA and RalB exhibit the most signiﬁcant sequence divergence in
their C-terminal membrane targeting sequences (50% identity)
(Fig. 1C). This sequence divergence results in their distinct subcellular
localization that contributes to the functional differences described for
RalA and RalB by regulating effector utilization in vivo [56,70–73].
Both isoforms can be found at the plasma membrane as well as in
endomembranes, with cell type differences seen. In this section we
summarize the role of post-translational modiﬁcations that regulate
Ral subcellular localization.
4.1. CAAX modiﬁcations
Like the majority of Ras family small GTPases, RalA and RalB termi-
nate in a CAAX (C = cysteine, A = aliphatic amino acid; X = terminal
amino acid) tetrapeptide motif (Fig. 4). The CAAX motif signals for a
series of post-translational modiﬁcations that increase hydrophobicity
and promotemembrane anchoring,where the terminal X residue deter-
mines protein prenyltransferase speciﬁcity [74]. When X= S, A, Q, and
M, the protein is preferentially recognized by farnesyltransferase
(FTase)-catalyzed addition of a C15 farnesyl isoprenoid lipid;
when X = L or I, it signals for geranylgeranyltransferase type I
(GGTase-I)-catalyzed addition of a C20 geranylgeranyl isoprenoid.
For Ral, the initial step is catalyzed by covalent addition of
geranylgeranyl to the cysteine residue of the CAAX motif by cytosolic
GGTase-I [75]. This is followed by endoproteolytic removal of the AAX
residues, catalyzed by endoplasmic reticulum-associated Ras
converting enzyme 1 (RCE1), and subsequent carboxymethylation of
the now terminal prenylated cysteine residue, catalyzed by
isoprenylcysteine carboxyl methyltransferase (ICMT).
The CAAX-signaled modiﬁcations are critical for both RalA and RalB
function. Mutation of the cysteine residue to prevent all CAAX-signaled
modiﬁcations disrupts Ral membrane association and function [75].
Similarly, treatment with a pharmacologic inhibitor of GGTase-I also
disrupted Ral membrane association and signaling. Since inhibition of
the GGTase-I modiﬁcation prevents all subsequent modiﬁcations, the
role of the Rce1 and ICMT catalyzed modiﬁcations in Ral function
remain to be addressed.
Recently, the Ral CAAX motifs were identiﬁed as members of a dis-
tinct subset of CA1A2X motifs where the A1 residue is a second cysteine
residue (CCAX). CCAX motifs can undergo an alternative modiﬁcation
pathway (Fig. 4). As shown for a Rho family small GTPase (Cdc42),
this motif can signal for dual lipid modiﬁcation: prenylation followed
by covalent addition of a palmitate fatty acid [76]. For Cdc42, after the
initial GGTase-I catalyzed prenylation step, a Golgi-associated protein
acetyltransferase (PAT) catalyzes covalent addition of palmitate to the
adjacent cysteine residue rather than the conventional modiﬁcation
by Rce1 and ICMT. For Cdc42, this alternative modiﬁcation prevented
its recognition by RhoGDI, a protein that masks the prenyl lipid and
disrupts membrane association, resulting in a cytosolic pool of Cdc42.
Since there is no known RalGDI, the consequences of this palmitate
modiﬁcation on Ral subcellular localization and membrane association,
and function, have not been determined.
4.2. Phosphorylation regulation of subcellular localization and effector
interaction
An emerging theme in the regulation of small GTPases is reversible
post-translational modiﬁcations that dynamically regulate subcellular
localization, thereby inﬂuencing effector interaction and biological
activity [77]. In particular, recent studies have highlighted protein
kinase-mediated phosphorylation of small GTPases in their C-terminal
membrane targeting regions. For example, K-Ras4B phosphorylation
by protein kinase C (PKC) on S181 in its C-terminal membrane
targeting sequence altered K-Ras4B subcellular localization [78].
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Ral -CCAX
Ral -C-OMe
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Fig. 4. Regulation of Ral subcellular localization and membrane association. CAAX motif-signaled post-translational modiﬁcations. Ral is geranylgeranylated by GGTase-1 on the ﬁrst
cysteine residue of the CAAX (RalA: CCIL; RalB: CCLL). By the canonical CAAX processing pathway, Ral is then modiﬁed at the endoplasmic reticulum (ER) by Ras converting enzyme
(Rce1) which cleaves between the two cysteine residues. Isoprenyl cysteine carboxyl methyltransferase (ICMT) then catalyzes methylation of the isoprenylated free cysteine residue,
facilitating recruitment to the plasma membrane. A second non-canonical pathway has been described by which Ral is palmitoylated at the cysteine residue at the A1 position by
Golgi-associated protein acetyltransferase (PAT) after geranylgeranylation. Palmitate addition is reversible and depalmitoylation is catalyzed by acylprotein thioesterase (APT). Whether
this double lipid modiﬁed form is associated with a different membrane compartment has not been determined. Ral subcellular localization is also regulated by a dynamic and reversible
protein kinase (PK)-mediated phosphorylation and protein phosphatase (PP)-mediated dephosphorylation cycle. RalA and RalB possess distinct C-terminal phosphorylation sites for
different protein kinases (PK). Phosphorylation causes dissociation from the plasmamembrane and translocation to speciﬁc endomembrane compartments, resulting in a switch in effec-
tor (E) interaction.
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whereas S181 phosphorylation K-Ras4B caused translocation to
mitochondrial and endoplasmic reticulum (ER) membranes. S181
is positioned within a polybasic amino acid stretch in K-Ras4B that
serves as a second signal that together with the CAAX modiﬁcations
promote full plasma membrane association. The negative charge
caused by phosphorylation reduces the positive charge of the
polybasic stretch. The ER-associated K-Ras4B then associated with
inositol trisphosphate receptors (InsP3) on the ER in a Bcl-xL-
dependent fashion, blocking the ability of Bcl-xL to potentiate the
InsP3 regulated ﬂux of calcium from ER to mitochondria that is
required for respiration, inhibition of autophagy, and cell survival
[79].
The Ral proteins are also regulated by similar mechanisms, with
distinct protein kinases phosphorylating serine residues distinct for
the C-termini of RalA and RalB (Fig. 4). Aurora-A kinase and protein
kinase A (PKA) have been found to phosphorylate RalA on S194 [80,
81] and protein phosphatase 2A dephosphorylates RalA at S194 as
well as S183 [82]. Counter and colleagues showed that phosphorylation
of RalA on S194 was critical for RalA to promote the anchorage-
independent growth in vitro and tumorigenic growth in nude mice of
pancreatic ductal adenocarcinoma (PDAC) cell lines [71]. This phos-
phorylation event dramatically altered RalA subcellular localization
from the plasma membrane to internal membranes, where it had an
enhanced interactionwith RalBP1. More recently, Aurora-A phosphory-
lation of RalA has been found to promote RalA translocation to the outer
face of mitochondria, where it then recruits RalBP1 to stimulate mito-
chondrial ﬁssion [57].
Studies by our lab and others have found that RalB is similarly regu-
lated by PKCα phosphorylation of S198 in the C-terminal membrane
targeting sequence [72,81]. In one study, it was found that S198 phos-
phorylation caused RalB translocation from the plasma membrane to
endocytic vesicles [72]. Associated with this change in subcellular local-
ization was a switch in effector utilization. Whereas unphosphorylated
RalA preferentially associated with Sec5, S198 phosphorylation caused
preferential association with RalBP1. Phosphorylation of RalB S198
was necessary for proper exocytic vesicle trafﬁcking and fusion at the
plasma membrane, with delivery of surface alpha-5 integrin being reg-
ulated by dynamic RalB phosphorylation. Independently, Theodorescuand colleagues found that phosphorylation of RalB S198 was critical in
regulating the ability of RalB to promote the metastatic growth of
bladder cancer cells in a nude mouse model [81].
4.3. Ubiquitination
In the past few years, regulation of small GTPases by ubiquitination
has gained recognition [77]. For example, monoubiquitination of
K-Ras on K147 reduces GAP sensitivity, thus allowing K-Ras to
remain active and signaling in the absence of upstream input [83].
Ubiquitination of the Ral proteins has also been shown to inﬂuence
their activity and function. Regulation of the ubiquitination of RalA
modulated RalA activity as well as lipid raft exposure [84]. Furthermore,
ubiquitination of RalB promoted binding to Sec5 to regulate innate
immunity, whereas deubiquitination allowed for binding to Exo84 and
subsequent induction of autophagy [85].
5. Ral function in invertebrates — lessons learned from worms and
ﬂies
The conservation of Ral GTPases, their regulators, and effectors in
Drosophila melanogaster and C. elegans has allowed genetic dissection
of Ral function. Consistent with the probable double genome duplica-
tion and subsequent winnowing of vertebrate relative to invertebrate
genomes [86], in Drosophila and C. elegans there exist single genes for
most Ras and Ral signaling components. For example, Drosophila and
C. elegans each harbors single Ral GTPase (two in mammals) and
RalGEF/RalGDS (four inmammals;Drosophila but not C. elegans encodes
a RalGPS ortholog), RalGAP α and β (two and one in mammals, respec-
tively) genes. This trend is consistent with reduced gene complexity of
other invertebrate Ras system signaling genes, with three mammalian
Ras, three Raf, and four type I PI3K catalytic subunit encoding genes
[87]. Generally, functional similarity between an invertebrate protein
and a speciﬁc vertebrate isoform is difﬁcult to extrapolate, largely
because biological assays usually differ between invertebrates and
mammals. But this difference also highlights the beneﬁt of invertebrate
studies, since they provide unique in vivo perspectives that comple-
ment mammalian studies. All key Ral effectors are conserved in
C. elegans and Drosophila but TBK1, which is not encoded in the
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C. elegans and Drosophila Ral signaling.
5.1. Toggling Ras between Raf and RalGEF regulation
Since RalGEFs and other Ras effectors are widely expressed, how Ras
effector utilization is regulated has been an unresolved issue. The
C. elegans vulva is patterned by epidermal growth factor (EGF) activa-
tion of Ras (LET-60) and the Raf–MEK–ERK MAP kinase cascade to
control 1° fate, and presumptive 1° cells secrete DSL Notch ligands to
induce 2° fate in neighboring cells. Furthermore, a spatial EGF gradient,
in addition to inducing 1° fate, contributes to 2° fate via an unknown
pathway. 1° and 2° cell fates are antagonistic and mutually exclusive.
Reiner and colleagues found that in addition to its canonical effector,
Raf, vulval Ras utilized RalGEF–Ral 2°-promoting activity to antagonize
Ras–Raf 1°-promoting activity, and that Ral promoter activity was
excluded from presumptive 1° cells, thus blocking inappropriate Ral
activation in 1° cells [88] (Fig. 5). Consistent with its restricted expres-
sion pattern, they found that Ras–RalGEF–Ral mediated the 2°-promot-
ing activity of the EGF gradient. These ﬁndings delineated a Ras effector-
switching mechanism whereby cell position within the morphogen
gradient dictates that LET-60/Ras effector usage switched from Raf to
RalGEF to promote 2° instead of 1° fate. This dynamic developmental
switching in effector use may reﬂect diversity in tumorigenic processes
that results in heterogeneity of effector predominance in tumors [89].
Other mechanisms that control Ras effector utilization will likely exist.
5.2. Ral and innate immunity
A recent study in mammalian cells showed that RalA mediates
nuclear translocation and activation of FOXO in response to reactive
oxygen species (ROS) by activating a JNK cascade scaffolded by JIP1,
and that in C. elegans RAL-1 and JIP-1 mediate DAF-16/FOXO
ROS-dependent nuclear translocation [90]. Additionally, transportin-1
mediates ROS-dependent nuclear translocation of DAF-16/FOXO inLIN-3/EGF
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Fig. 5. EGFR signaling toggles C. elegans developmental output by effector switching. The C. eleg
(RGL-1). The nearby anchor cell (AC) secretes EGF/LIN-3, creating a concentration gradient, indu
with sequential induction, patterns vulval cell fates. Active pro-1° signaling is shown inblue,wit
cells, typically P6.p, EGF activates Ras to utilize Raf to promote 1° cell fate. Pro-2° signaling th
from presumptive 1° cells. Additionally, presumptive 1° cells express and secrete notch ligand
Notch/LIN-12 receptor to assume a 2° fate. In presumptive 2° cells, Notch induces expression of
EGF activates Ras to utilize the RGL-1 RalGEF effector to promote 2° fate.both mammals and C. elegans [91]. C. elegans harbors a single FOXO
gene, daf-16, compared to four mammalian genes. These observations
suggest that Ral-mediated stress response to ROS is conserved across
evolution.
As noted above, mammalian RalB harnesses the TBK1 IκB kinase
family member for tumor cell survival. These results are echoed in
Drosophila, where Sec5 or Ral haploinsufﬁciency reduces anti-fungal
response [61]. The absence of TBK1 and other IκB-related proteins in
the worm genome may reﬂect the absence of NF-κB in the worm
genome and attendant differences in innate immunity [92].5.3. Fly insights into Ral signaling partners
Yeast two-hybrid interaction studies in Drosophila identiﬁed the Ral
effectors Sec5 and RalBP1/RLIP, and RalBP1/RLIP bindswith knownpart-
ner REPS1 [93]. Upstream of Ral, both ﬂy Ras and ﬂy Rap bind RalGEF in
yeast two-hybrid assays, consistent with their identical core effector
binding regions. However, in mammalian systems Ras and Rap1 are
localized to mostly non-overlapping subcellular compartments, and it
is expected that they encounter distinct sets of effectors [94,95]. Overex-
pression studies with the two splice variants of the ﬂy RalGEF suggest
that one alternative isoform, differing in N-terminal sequence, harbors
Ral-independent functions. This putative GEF-independent function
of RalGEF may correspond to putative N-terminally encoded
GEF-independent functions of mammalian RalGDS, where RalGDS is
thought to scaffold PDK and Akt, thus potentiating Akt output in certain
circumstances [96,97]. Genetic analyses, mostly using ectopically
expressed constructs, implicate the Rap1 small GTPase, rather than
Ras, as a putative activator of RalGEF. However, these results are also
consistent with Rap1 functioning in parallel, and illustrate the potential
complexities of dominant negative mutations as experimental tools for
small GTPases, as well as the difﬁculties of analyzing the functions of
essential genes in vivo [98]. The Ras, Rap1 and Ral small GTPases act in
multiple developmental events during Drosophila development, so
there is ample opportunity to study their functions further.LET-23/EGFR
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LIN-12/Notch
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MEK-2/MEK 
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ans Ras ortholog (LET-60) can interact with orthologs of human Raf (LIN-45) and RalGEF
cing vulval precursor cell (VPC) development. This concentration gradient, in combination
h active pro-2° signaling shown in red, and quenched signaling is in gray. In presumptive 1°
rough Notch is quenched. RGL-1→ RAL-1 pro-2° quenching is based on RAL-1 exclusion
(DSL; Delta/Serrate/LAG-2) that then induces neighboring vulval precursor cells via the
an ERKMAPK phosphatase, and other 2°-speciﬁc proteins to quench the Raf pro-1° signal.
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coupled with yeast two-hybrid gene discovery and mammalian
biochemical experiments, identiﬁed an interesting and otherwise
unidentiﬁed Ral effector cascade [99]. Ral signals through Sec5 of the
exocyst complex, which in turn interacts with the Msn MAP4 kinase
in ﬂies and humans. Msn is thought to signal through a basket/JNK
MAP kinase cascade in ﬂies, and its ortholog HGK signals through a
JNK MAP kinase cascade in human cells. The ﬂy Msn and human HGK
proteins are members of the CNH domain-containing MAP4 kinases,
which contain ancient Ste20-like kinase domains thought to activate
JNK and p38 MAP kinases cascades. Drosophila encodes two family
members (Msn and Hpy), C. elegans encodes two family members
(MIG-15 and GCK-2), and mammals contain eight distinct genes
encoding CNH domain-containingMAP4 kinases, with four correspond-
ing to each invertebrate subgroup [100]. This relatively under-
investigated group of kinases may represent a new and druggable Ral
signaling output.
5.4. RalGAPs connect Ral with the mTORC1 signaling network
An unexpected crosstalk between the Ral and mTOR signaling
networks was identiﬁed through the sequence relationship shared
with the GAPs that control each network. mTOR signaling regulates a
spectrum of major cellular processes and is implicated in cancer and
other pathologic conditions [30]. Despite the sequence identity with
TSC2 (26–27% identity in RalGAP domains) (Fig. 2D), RalGAPs do not
exhibit GAP activity for Rheb in vitro or in vivo [31]. Nevertheless, the
unexpected observation that C. elegans possesses orthologs for the
Rheb and Ral GTPases and for RalGAPα/β, but not Tsc1/2, led to the
discovery of an unexpected signaling interplay between Ral and Rheb
signaling [31]. It was determined that C. elegans RalGAP loss caused
decreased lifespan, consistent with a Tsc-like function. Additionally,
RalGAP suppression in mammalian cells caused RalB-selective activa-
tion and Sec5- and exocyst-dependent engagement of the mTORC1
complex and suppression of autophagy (Fig. 3). Surprisingly, it was
also found that Tsc1–Tsc2 loss activated RalA/B independently of
Rheb-mTOR signaling. Finally, RalGAP suppression caused mTORC1-
dependent pancreatic tumor cell invasion. These ﬁndings identify an
unexpected crosstalk and integration of the Ral and mTORC1 signaling
networks.
Interestingly, as noted abovemammalianRalB also activates autoph-
agy, an activity supported by Drosophila experiments [34]. Since TORC1
inhibits autophagy [101,102], the observations that RalB both promotes
and inhibits autophagy are potentially contradictory. However,
RalB–TORC1 signaling occurs at the plasma membrane while RalB-
autophagosome signaling occurs at the lysosome/autophagolysosome.
The aforementioned observations of phosphorylation-dependent
subcellular trafﬁcking and effector switching of K-Ras [78] and RalA
[82] raise the possibility that RalB can orchestrate seemingly antagonis-
tic signaling outcomes under different conditions and in different cellu-
lar compartments.
6. Ral and cancer
Since RalGEFs participate in downstream signaling from activated
Ras proteins, it was initially speculated that Ral protein activation may
contribute to Ras-driven cellular transformation. However, when
explored initially in NIH 3T3 mouse ﬁbroblasts, a critical and signiﬁcant
role for Ral GTPases in Ras-driven cancer seemed unlikely [103,104].
However, when Counter and colleagues explored the role of Ral
in Ras-mediated growth transformation of immortalized human
astrocytes, ﬁbroblast or epithelial cells, a more signiﬁcant role for Ral
GTPases as effectors of Ras in human cancer was observed, suggesting
species differences in the effectors that are important in Ras oncogene
function [105].That Ral GTPases serve critical roles in human cancer cell growth
gained greater traction when White and colleagues found that RalB
was critical for tumor but not normal cells for survival, while RalA was
necessary for the anchorage-independent growth of cancer cells [106].
Importantly, this also marked the ﬁrst time RalA and RalB were found
to have non-overlapping functions. Since these key studies, a major
theme of Ral proteins is their signiﬁcant and often divergent roles in
numerous cancer types. In the following section we review some of
the key ﬁndings made with regard to the role of the two Ral isoforms
as drivers in different human cancers. Since the RA domain-containing
RalGEFs can be activated by other Ras family small GTPases, as well as
by non-Ras mechanisms, and since some RalGEFs are regulated by
non-Ras mechanisms, an involvement of Ral in cancers where RAS
mutations are not common is not surprising.
6.1. Bladder carcinoma
Evaluation of a panel of human bladder cancer cell lines found
preferentially increased levels of activated RalA and RalB in RASmutant
[107] or invasive cell lines [108]. Using RNAi or ectopic expression of
activated Ral mutants, Theodorescu and colleagues found that RalA
and RalB played antagonistic roles in the migratory activity of the
KRAS-mutant UM-UC-3 bladder cancer cell line, with RalA suppressing
and RalB enhancing motility [109].
Activating RASmutations occur in a low percentage (~10%) of blad-
der cancers. Therefore, a Ras–RalGEF mechanism may be less relevant
for Ral activation in this cancer type. Consistent with this possibility, a
recent study foundRalGAPα2 expression in normal bladder urothelium,
but reduced expression associated with advanced clinical stage and
poor patient survival [108]. Furthermore, genetic depletion of Ralgapα2
in mice did not cause any apparent abnormalities but did enhance the
invasive phenotype of chemically-induced bladder tumors. Thus, loss
of RalGAP function may be an important mechanism for Ral activation
in bladder cancer.
6.2. Colorectal carcinoma
Oncogenic KRAS and NRAS mutations occur in 45% and 8%, respec-
tively, of colorectal cancer (CRC) tumors. Ral signaling has been
shown to be a critical regulator of the anchorage-independent growth
properties of CRC tumor cells [110]. Martin et al. found that RNAi-
mediated suppression of RalA resulted in a decrease in soft agar colony
growthwhile loss of RalB had the opposite effect, leading to an enhance-
ment of anchorage-independent growth. They found that RalA and RalB
modulated this phenotype by utilizing both common and distinct effec-
tor proteins. Using Ral effector binding mutants that are selectively
uncoupled from Exo84, Sec5, or RalBP1, they showed that RalA required
Exo84 and RalBP1 binding to promote the anchorage-independent
growth of CRC cells. Conversely, RalB required Sec5 and RalBP1 to
suppress soft agar colony formation. Intriguingly, loss of one Ral isoform
was found to increase the activation of the other isoform suggesting
compensatory crosstalk betweenRalA and RalB.What speciﬁcallymedi-
ates this crosstalk between RalA and RalB is unknown, but it could be
through either enhanced RalGEF accessibility for the remaining Ral
protein or a downregulation of RalGAP activity upon single Ral isoform
depletion. Depletion of RalB has also been shown to cause apoptosis in
colorectal cancer cells [61].
6.3. Hepatocellular carcinoma
RAS mutations are rare (N2%) in hepatocellular carcinoma (HCC).
RalA was found to be signiﬁcantly overactivated in hepatocellular
carcinoma (HCC) cells and tissues compared to nonmalignant samples.
Suppression of RalA expression caused a signiﬁcant decrease in the viabil-
ity and invasiveness of HCC cells. A role for RalBwas not addressed. Final-
ly, in a transgenic mouse model for HCC (farnesoid X receptor-
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tumors [111].
6.4. Lung adenocarcinoma
KRAS mutations are found in 30% of lung adenocarcinomas and
several studies have addressed the role of Ral in lung cancer. In one
study, variable levels of RalA-GTP, independent ofKRASmutation status,
were detected in a panel of lung adenocarcinoma or squamous carcino-
ma cell lines [112]. shRNA suppression of RalA expression in the KRAS
mutant A549 lung adenocarcinoma cell line reduced the proliferation
and invasion in vitro. In a secondmore comprehensive study, immuno-
histochemistry analyses of non-small cell lung cancers (NSCLC), it was
found that high RalA and RalB protein expression was associated with
poor survival. The levels of activated RalA but not RalB were higher in
KRAS-mutant NSCLC cell lines [113]. Depletion of RALA or RALB or both
reduced anchorage-dependent and –independent growth for either
KRASmutant and wild type cell lines. Depletion of RALA, RALB, or both
also impaired the tumorigenic growth of KRAS-mutant NSCLC cells.
Interestingly, very limited analyses in this and another study suggested
mutation-selective involvement of Ral in NSCLC, where KRAS G12C
mutant NSCLC cell lines showed greater activation and/or dependence
on Ral for growth [114].
In contrast to human lung tumor cell line studies, RalA and RalB
were found to exhibit redundant functions when assessed in mouse
development and in a Kras G12D-driven mouse model of lung adeno-
carcinoma [73]. Ralb deﬁcient mice were viable with no overt pheno-
type whereas a Rala deﬁciency caused embryonic lethality that was
further exacerbated by a combined Ralb deﬁciency. Neither a Rala nor
a Ralb deﬁciency impaired Kras-driven lung tumor development. How-
ever, a combined loss of both Rala and Ralb signiﬁcantly reduced lung
tumor development. These results suggest redundancy in RalA and
RalB function for tumor development. One possible explanation for
this different conclusion may be that the human lung tumor cell line
studies addressed the role of Ral in tumor maintenance whereas
the mouse study addressed the role of Ral in tumor initiation and
progression.
6.5. Malignant peripheral nerve sheath tumors
Loss of the NF1 RasGAP, rather than RAS mutational activation, is
seen in neuroﬁbromatosis type 1 and malignant peripheral nerve
sheath tumors (MPNST) [115].When comparedwith a nontransformed
mouse Schwann cell line, RalA-GTP levels were elevated in a panel of
MPNST cell lines established from tumors that arose from a NF1- and
Tp53-deﬁcient genetically-engineered mouse model. When evaluated
in one cell line, RalA suppression impaired proliferation and invasion
in vitro and tumorigenic growth in vivo [116]. RalA activation was also
seen in human MPNST cell lines and tissue, and restoration of NF1
GAP activity reduced RalA activity, indicating that this was associated
with Ras activation.
6.6. Melanoma
RASmutations, predominantly NRAS, occur in 28% of skin cutaneous
melanomas. With BRAFmutations seen in 60% of melanomas in a non-
overlapping frequency with RASmutations, activation of the canonical
Raf–MEK–ERK mitogen-activated protein kinase (MAPK) pathway
alonemay seem to be sufﬁcient for Ras-drivenmelanomagrowth. How-
ever, analysis of Ral activation in a panel of human melanoma cells
showed a consistently high level of total and activated RalA, but not
RalB, activation that was independent of NRAS or BRAFmutation status
[117]. Additionally, RalA and to a lesser degree RalB are necessary for
the tumorigenic growth of melanomas, also regardless of BRAF and
NRASmutation status.Studies using tumor suppressor Arf-deﬁcient immortalized mouse
melanocytes to investigate the contributions of Ras downstream signal-
ing to melanomagenesis also indicated a role for Ral signaling [118].
Ectopic expression of the RalGEF Rgl2 engineered to contain a mem-
brane localization sequence (to mimic Ras activation of RalGEF) was
sufﬁcient to promote the anchorage-independent growth and Matrigel
invasion of these melanocytes similar to that caused by oncogenic
N-Ras. Surprisingly, in contrast, activated BRAF V600E did not enhance
proliferation or invasion. Finally, ectopic expression of a dominant neg-
ative mutant of RalB that blocks RalGEF function partially impaired the
growth ofNRAS-transformedmelanocytes. Thus, togetherwith theﬁnd-
ings of Zipfel et al. [117], Ral GTPases can act as drivers of melanoma
cancer growth in both RAS wild type and mutant cancer cells.
6.7. Ovarian carcinoma
One study has now revealed that Ral signaling has a role in ovarian
cancer. Speciﬁcally, higher levels of RalA activity was found in human
tumor samples compared to benign samples. Furthermore, depletion
of RalA decreased proliferation and invasion of ovarian cancer cell line
OVCAR-5 in vitro and decreased tumor genesis [119].
6.8. Pancreatic ductal adenocarcinoma
A signiﬁcant requirement for activated Ral signaling in pancreatic
adenocarcinoma (PDAC) cell line tumorigenic and invasive growth has
been established. Human PDAC has a high frequency or activating
KRASmutations and Ral activation is seen in both human tissue samples
and tumor cell lines [120–122]. Interestingly, activation of RalA was
found at a higher frequency than the activation of either ERK or AKT
in PDAC cells, suggesting a critical role for the RalGEF–Ral pathway
downstream of oncogenic K-Ras.
Depletion of RalA and RalB via RNAi has elucidated roles for RalA in
anchorage-independent and tumorigenic growth and RalB in invasive
and metastatic growth of PDAC cells [122]. PDAC cells with stable
RNAi depletion of RalA results in reduced subcutaneous tumor forma-
tion upon injection into immune compromised mice. These same cells
expressing RalB RNAi do not form lung metastases post-injection into
the tail-vein of nude mice. In addition to playing a role in tumor initia-
tion, RalA has also been shown to be necessary for PDAC tumor mainte-
nance. The use of inducible RNAi to stably deplete RalA from established
primary tumors resulted in regression of the tumor, indicating a neces-
sity for persistent RalA signaling in established PDAC tumors.
There is also recent evidence that active K-Ras signaling to RalB but
not RalA plays a critical role in the formation of invadopodia in PDAC
cells [56]. Invadopodia are actin-rich membrane protrusions that are
known to be involved in the secretion of matrix metalloproteases
(MMP) during tumor cell invasion. RalB requires the ability to interact
with RalBP1 to mediate this process and RalBP1 itself is necessary for
the formation of invadopodia in PDAC cells. Surprisingly, the RhoGAP
activity of RalBP1 is not necessary for invadopodia formation while
the ATPase activity is required. Why the ATPase activity is necessary
for RalBP1 to mediate invadopodia formation is unclear.
RalGEFs have also been found to play a role in PDAC. Rgl2 is
overexpressed in PDAC patient tumors and has been shown to be neces-
sary for both the anchorage-independent and invasive growth of PDAC
tumor cells [123]. RNAi-mediated depletion of Rgl2 results in a signiﬁ-
cant decrease in both RalA and RalB activation. Interestingly, expression
of constitutively active RalA could not rescue soft agar growth after the
loss of Rgl2 indicating that Rgl2 may have non-Ral regulatory functions
or that the RalA interaction with Rgl2 is critically important for the
regulation of anchorage-independent growth. Rgl2 was found to be
co-localized with RalB but not RalA at the leading edge of migrating
CFPac-1 PDAC cells. Loss of Rgl2 results in a loss of RalB from the leading
edge, perhaps giving insight into how themigratory and invasive activ-
ity of PDAC cells relies on Rgl2/RalB signaling.
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Increased RalA-GTP levels were observed in the RAS wild type
human prostate carcinoma cell line PC3. Suppression of RalA did not
impair tumor formation but did abolish bone metastasis [124]. In
contrast, suppression of RalB expression did not impair metastasis.
6.10. Squamous cell carcinoma
Squamous cell carcinoma is the second most common type of skin
cancer. Using an in vitro model of Ras-induced human squamous cell
carcinoma (SCC) of the skin, it was found that RalA suppressed rather
than promoted progression [125]. Suppression of RalA but not RalB
stimulated the progression of HRAS-transformed human keratinocytes
to a more invasive state.
In contrast to the in vitro observations, different roles for Ral were
observed in a mouse model of carcinogen-induced SCC [73]. Single
application of the mutagen DMBA, followed by repeated applications
of phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) causes
Hrasmutation and the development of benign papillomas, with a subset
progressing to SCC. Neither a Rala nor a Ralb deﬁciency impaired papil-
lomadevelopment. As described above for Kras-driven lung adenocarci-
noma formation, only combined loss of both Rala and Ralb signiﬁcantly
reduced papilloma development. Genetic ablation of Ralgds in this same
carcinogenesis model also signiﬁcantly reduced tumor incidence, size,
and progression [126].
7. Conclusions and future prospects
Ral GTPase signaling has emerged as being critically important in
both normal and neoplastic cell physiology. Over the last two and a
half decades we have learned a great deal about how Ral proteins regu-
latemany biological processes. From these studies one of themost strik-
ing observations has been the very distinct functions observed for RalA
and RalB despite similar structural and biochemical properties and
shared effector utilization. Do these distinct functions simply reﬂect to
spatially distinct interactions with the same set of effectors or are their
Ral isoform selective effectors that remain to be discovered. Only
recently have RalGAPs been discovered and much more remains to be
learned regarding their roles in regulation of Ral activity and signaling.
With increasing evidence for key roles for Ral GTPases as drivers in
cancer growth, it will be important to identify pharmacologic
approaches for targeting aberrant Ral function for cancer treatment.
Like Ras, Ral proteins are not tractable therapeutic targets, although
recent progress in the identiﬁcation of direct Ras binders suggests that
small GTPases may yet be targeted directly. If not, indirect approaches
need to be explored. With kinases implicated as downstream effectors
or key regulators of Ral GTPases, can these be exploited for anti-Ral
drug development? In summary, withmore still to be learned regarding
Ral function, it is quite certain that there will be more than 15 minutes
remaining in their fame.
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